Showing Results for
- Academic Journals (28)
Search Results
- 28
Academic Journals
- 28
- Search Terms:
- 1From: Nature Reviews Drug Discovery. (Vol. 11, Issue 9) Peer-ReviewedAutophagy is a lysosomal degradation pathway that controls the quality of the cytoplasm by eliminating protein aggregates and damaged organelles. It is also involved in metabolic conditions, neurodegenerative diseases,...
- 2From: Nature Reviews Drug Discovery. (Vol. 11, Issue 9) Peer-ReviewedCurrent anti-obesity drugs aim to reduce food intake by either curbing appetite or suppressing the craving for food. However, many of these agents have been associated with severe psychiatric and/or cardiovascular side...
- 3From: Nature Reviews Drug Discovery. (Vol. 11, Issue 9) Peer-ReviewedCancer cells tend to shed tumour suppressor genes--and often delete neighbouring genes in the process. Now, reporting in Nature, DePinho and colleagues show that some of these 'passenger deletions' create cancer...
- 4From: Nature Reviews Drug Discovery. (Vol. 11, Issue 9) Peer-ReviewedAstraZeneca and BTG have stopped developing their Phase II sepsis candidate, leaving few drugs in the sepsis pipeline. The lowdown: Effective sepsis drugs have long eluded drug developers. Most of the trials that have...
- 5From: Nature Reviews Drug Discovery. (Vol. 11, Issue 9) Peer-ReviewedIn Alzheimer's disease (AD), toxic amyloid-[[beta].sub.42] (A[[beta].sub.42]) binds to and aberrantly signals through the [alpha]7-nicotinic acetylcholine receptor ([alpha]7nAchR). Using tissue from both mouse models of...
- 6From: Nature Reviews Drug Discovery. (Vol. 11, Issue 9) Peer-ReviewedThe persistence of latent HIV within T cells, which is maintained in part by the activity of histone deacetylases (HDACs), means that it is difficult to eradicate HIV infection. Archin et al. investigated the effects of...
- 7From: Nature Reviews Drug Discovery. (Vol. 11, Issue 9) Peer-ReviewedThe European Clinical Trials Directive was introduced at the turn of the millennium with a grand ambition: to harmonize the rules governing clinical researchers in all the EU member states. It failed, and medical...
- 8From: Nature Reviews Drug Discovery. (Vol. 11, Issue 9) Peer-ReviewedWe thank Professor Lentini for his comments on our article (Minimum information about a bioactive entity (MIABE). Nature Rev. Drug Discov. 10, 661-669 (2011)) (1) proposing guidelines for the minimum information about a...
- 9From: Nature Reviews Drug Discovery. (Vol. 11, Issue 9) Peer-ReviewedUnder US patent legislation, using a patented invention for uses that are related to the submission of information to the US Food and Drug Administration (FDA) is not an act of patent infringement. Although it is...
- 10From: Nature Reviews Drug Discovery. (Vol. 11, Issue 9) Peer-ReviewedSince the discovery of leptin in 1994, we now have a better understanding of the cellular and molecular mechanisms underlying its biological effects. In addition to its established anti-obesity effects, leptin exerts...
- 11From: Nature Reviews Drug Discovery. (Vol. 11, Issue 9) Peer-ReviewedShionogi-ViiV Healthcare has announced positive results from the Phase III SINGLE trial of their investigational HIV integrase inhibitor, dolutegravir, in treatment-naive adults with HIV-1. The dolutegravir-based...
- 12From: Nature Reviews Drug Discovery. (Vol. 11, Issue 9) Peer-ReviewedA public-private partnership to establish biomarkers of dementia in Down's syndrome could aid the development of preventive therapies for the dementia associated with both Down's syndrome and Alzheimer's disease, based...
- 13From: Nature Reviews Drug Discovery. (Vol. 11, Issue 9) Peer-ReviewedAlthough the development of obesity drugs has been plagued by failure, two novel therapies have recently received US Food and Drug Administration approval, the first in 13 years. In their Review, Dietrich and Horvath...
- 14From: Nature Reviews Drug Discovery. (Vol. 11, Issue 9) Peer-ReviewedObesity has become one of the most significant public health challenges of the twenty-first century. As a primary risk factor for type 2 diabetes, it is closely associated with the metabolic syndrome (a collection of...
- 15From: Nature Reviews Drug Discovery. (Vol. 11, Issue 9) Peer-ReviewedThe jumonji family of histone Demethylases--which catalyse the demethylation of lysine on histones through an oxidative reaction that requires [Fe.sup.2+] and [alpha]-ketoglutarate as cofactors--are involved in...
- 16From: Nature Reviews Drug Discovery. (Vol. 11, Issue 9) Peer-ReviewedA ruling by Europe's highest court means that it is now possible to be awarded a so-called supplementary protection certificate (SPC)--an extended form of market exclusivity following patent expiration--for new...
- 17From: Nature Reviews Drug Discovery. (Vol. 11, Issue 9) Peer-ReviewedThese two papers investigated indirectly restoring p53 tumour suppressor function as an anticancer strategy. Gembarska et al. showed that the p53 pathway is inactivated in ~65% of human melanomas as a result of...
- 18From: Nature Reviews Drug Discovery. (Vol. 11, Issue 9) Peer-ReviewedGenitorectal mucosal surfaces are key transmission sites for viruses, and the presence of antigen-specific CD[8.sup.+] cytotoxic T cells in the mucosa can protect against HIV and other sexually transmitted virus...
- 19From: Nature Reviews Drug Discovery. (Vol. 11, Issue 9) Peer-ReviewedThe formation of a vascular blood clot--thrombosis--can disrupt normal blood flow to major organs and is a leading cause of death worldwide. Although agents capable of dissolving such clots are available, their use is...
- 20From: Nature Reviews Drug Discovery. (Vol. 11, Issue 9) Peer-ReviewedArray's ARRY-797 met its primary efficacy end point in a Phase II osteoarthritis trial, potentially renewing interest in a troubled drug class. The lowdown: p38 mitogen-activated protein kinase inhibitors have been...